MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1

Claudia Marchetti, Federica Romano, Cinzia Marchese, Simona Ceccarelli, Enrica Vescarelli, Giulia Gerini, Francesca Megiorni, Eleni Anastasiadou, Paola Pontecorvi, Luciana Solito, Claudia De Vitis, Simona Camero, Rita Mancini, Pierluigi Benedetti Panici, Carlo Dominici, Ferdinando Romano, Antonio Angeloni

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: Ovarian cancer (OC) is the most lethal gynecological malignancy and the second leading cause of cancer-related death in women. Treatment with PARP inhibitors (PARPi), such as Olaparib, has been recently introduced for OC patients, but resistance may occur and underlying mechanisms are still poorly understood. The aim of this study is to identify target genes within the tumor cells that might cause resistance to Olaparib. We focused on Neuropilin 1 (NRP1), a transmembrane receptor expressed in OC and correlated with poor survival, which has been also proposed as a key molecule in OC multidrug resistance. Methods: Using three OC cell lines (UWB, UWB-BRCA and SKOV3) as model systems, we evaluated the biological and molecular effects of Olaparib on OC cell growth, cell cycle, DNA damage and apoptosis/autophagy induction, through MTT and colony forming assays, flow cytometry, immunofluorescence and Western blot analyses. We evaluated NRP1 expression in OC specimens and cell lines by Western blot and qRT-PCR, and used RNA interference to selectively inhibit NRP1. To identify miR-200c as a regulator of NRP1, we used miRNA target prediction algorithms and Pearsons' correlation analysis in biopsies from OC patients. Then, we used a stable transfection approach to overexpress miR-200c in Olaparib-resistant cells. Results: We observed that NRP1 is expressed at high levels in resistant cells (SKOV3) and is upmodulated in partially sensitive cells (UWB-BRCA) upon prolonged Olaparib treatment, leading to poor drug response. Our results show that the selective inhibition of NRP1 is able to overcome Olaparib resistance in SKOV3 cells. Moreover, we demonstrated that miR-200c can target NRP1 in OC cells, causing its downmodulation, and that miR-200c overexpression is a valid approach to restore Olaparib sensitivity in OC resistant cells. Conclusions: These data demonstrate that miR-200c significantly enhanced the anti-cancer efficacy of Olaparib in drug-resistant OC cells. Thus, the combination of Olaparib with miRNA-based therapy may represent a promising treatment for drug resistant OC, and our data may help in designing novel precision medicine trials for optimizing the clinical use of PARPi.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume39
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • Drug resistance
  • miR-200c
  • PARP inhibitors
  • NRP1
  • Ovarian cancer
  • miRNAs

Fingerprint

Entra nei temi di ricerca di 'MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1'. Insieme formano una fingerprint unica.

Cita questo